دورية أكاديمية
Real-World Clinical Experience of Rosuvastatin as a Lipid-Lowering Therapy for Primary and Secondary Prevention of Cardiovascular Events (REAL ROSE).
العنوان: | Real-World Clinical Experience of Rosuvastatin as a Lipid-Lowering Therapy for Primary and Secondary Prevention of Cardiovascular Events (REAL ROSE). |
---|---|
المؤلفون: | Mehta A; Cardiology, Dr Ashwani Mehta Clinic, New Delhi, IND., Jain P; Cardiology, Indraprastha Apollo Hospitals, New Delhi, IND., Patil R; Internal Medicine, Sevasadan Lifeline Superspecialty Hospital, Miraj, IND., Sashi Kant T; Internal Medicine, Sri Sai Heart Care Clinic, Hyderabad, Hyderabad, IND., Indurkar SA; Internal Medicine, Diabetes Clinic, Aurangabad, IND., Kota SK; Internal Medicine, Diabetes & Endocare Clinic, Berhampur, IND., Revankar S; Scientific Services, USV Private Limited, Mumbai, IND., Gupta A; Scientific Services, USV Private Limited, Mumbai, IND. |
المصدر: | Cureus [Cureus] 2022 Nov 14; Vol. 14 (11), pp. e31468. Date of Electronic Publication: 2022 Nov 14 (Print Publication: 2022). |
نوع المنشور: | Journal Article |
اللغة: | English |
بيانات الدورية: | Publisher: Cureus, Inc Country of Publication: United States NLM ID: 101596737 Publication Model: eCollection Cited Medium: Print ISSN: 2168-8184 (Print) Linking ISSN: 21688184 NLM ISO Abbreviation: Cureus Subsets: PubMed not MEDLINE |
أسماء مطبوعة: | Original Publication: Palo Alto, CA : Cureus, Inc. |
مستخلص: | Background Rosuvastatin effectively reduces endogenous cholesterol synthesis and low-density lipoprotein (LDL) cholesterol and increases high-density lipoprotein (HDL) cholesterol. This study aimed to evaluate the clinical characteristics of patients and treatment patterns of rosuvastatin as a lipid-lowering therapy for primary and secondary prevention of cardiovascular events in Indian settings. Methods This real-world, retrospective multi-centric observational study included patients aged >18 years who received treatment with a rosuvastatin/rosuvastatin-based combination. Demographic and data about concomitant diseases and medications were recorded. Results Out of 1,816 patients, the majority were men (66.2%); the mean age was 54.1 years. The patients prescribed rosuvastatin for primary and secondary prevention of cardiovascular events were 71.9% and 28.1%, respectively. Rosuvastatin 10 mg (56.8%) was the most commonly prescribed dose. For primary prevention, 10 mg (65.0%) was the most preferred dose, and for secondary prevention, 20 mg (54.3%) was the most preferred dose. Rosuvastatin treatment significantly (pre- vs. post-treatment) reduced the levels of total cholesterol (227.2 vs. 178.4 mg/dL), triglycerides (212.6 vs. 154.4 mg/dL), and LDL cholesterol (167.0 vs. 125.6 mg/dL), and increased HDL cholesterol levels (40.7 vs. 44.3 mg/dL) (p<0.0001). A total of 1,196 patients received combination therapy with rosuvastatin (aspirin, 34.0%, and fenofibrate, 21.9%). Adverse events were reported in 0.4% of the study population (leg pain, nausea, muscle cramps/pain, bleeding, and myalgia). Conclusion This study demonstrated the clinical effectiveness and safety of moderate- to high-intensity rosuvastatin (5-40 mg) for primary and secondary prevention of cardiovascular events in the Indian population. A primary prevention strategy with statins can reduce cardiovascular events and associated morbidity and mortality. Competing Interests: The authors have declared financial relationships, which are detailed in the next section. (Copyright © 2022, Mehta et al.) |
References: | J Clin Diagn Res. 2016 Jul;10(7):OE01-5. (PMID: 27630892) Eur Heart J. 2016 Aug 1;37(29):2315-2381. (PMID: 27222591) Lancet Neurol. 2009 May;8(5):453-63. (PMID: 19375663) Stroke. 2014 Jul;45(7):2160-236. (PMID: 24788967) N Engl J Med. 2006 Aug 10;355(6):549-59. (PMID: 16899775) Circulation. 2019 Jun 18;139(25):e1046-e1081. (PMID: 30565953) Lancet Glob Health. 2018 Dec;6(12):e1339-e1351. (PMID: 30219317) Lipids Health Dis. 2017 Jul 3;16(1):130. (PMID: 28673294) Circ Cardiovasc Qual Outcomes. 2019 Apr;12(4):e005195. (PMID: 30917685) J Assoc Physicians India. 2016 Mar;64(3 suppl):7-52. (PMID: 28762263) Stroke. 2019 Dec;50(12):e344-e418. (PMID: 31662037) N Engl J Med. 2018 Oct 18;379(16):1509-1518. (PMID: 30221597) Indian Heart J. 2017 May - Jun;69(3):382-392. (PMID: 28648438) Diabetes Care. 2020 Aug;43(8):1977-1978. (PMID: 32503834) JACC Cardiovasc Imaging. 2019 Aug;12(8 Pt 1):1518-1528. (PMID: 30553686) PLoS One. 2014 May 09;9(5):e96808. (PMID: 24817067) J Assoc Physicians India. 2020 Jul;68(7):57-61. (PMID: 32602682) J Assoc Physicians India. 2018 Mar;66(3):70-4. (PMID: 30341873) N Engl J Med. 2018 Oct 18;379(16):1529-1539. (PMID: 30146931) Am J Cardiol. 2014 May 15;113(10):1753-64. (PMID: 24792742) J Family Med Prim Care. 2020 Aug 25;9(8):4156-4164. (PMID: 33110825) Circulation. 2014 Jun 24;129(25 Suppl 2):S1-45. (PMID: 24222016) Eur J Prev Cardiol. 2017 Aug;24(12):1294-1296. (PMID: 28504565) Circulation. 2019 Sep 10;140(11):e596-e646. (PMID: 30879355) Lancet. 2009 May 30;373(9678):1849-60. (PMID: 19482214) Clin Med Insights Cardiol. 2012;6:17-33. (PMID: 22442638) Eur Heart J. 2020 Jan 1;41(1):111-188. (PMID: 31504418) |
فهرسة مساهمة: | Keywords: dose titration; dyslipidemia; high-intensity; rosuvastatin; statins |
تواريخ الأحداث: | Date Created: 20221216 Latest Revision: 20221221 |
رمز التحديث: | 20231215 |
مُعرف محوري في PubMed: | PMC9748627 |
DOI: | 10.7759/cureus.31468 |
PMID: | 36523717 |
قاعدة البيانات: | MEDLINE |
تدمد: | 2168-8184 |
---|---|
DOI: | 10.7759/cureus.31468 |